Gilead's newly approved cancer drug priced at $373,000

In this video

Share

Gilead's newly approved cancer drug priced at $373,000

CNBC's Meg Tirrell reports on the FDA approving Gilead's cancer drug and what its priced at.
01:22
Wed, Oct 18 20175:53 PM EDT